Prevalence of Portopulmonary Hypertension in Patients with Hepatic Cirrhosis
DOI:
https://doi.org/10.70749/ijbr.v3i7.1674Keywords:
Portopulmonary Hypertension, Hepatic CirrhosisAbstract
Objective: “To determine the frequency of portopulmonary hypertension in patients with hepatic cirrhosis.” Study Place and Duration: Department of Medicine, Ghurki Trust Teaching Hospital, Lahore for 05 months from 7th Feb 2025 to 8th June 2025. Methodology: After meeting the selection criteria, 130 patients were and underwent portal vein Doppler ultrasound and echocardiography. Portopulmonary hypertension was diagnosed if the patient had a tricuspid regurgitation velocity ≥2.8 m/s, an estimated pulmonary artery systolic pressure >35 mmHg on echocardiography, pulmonary arterial pressure >20 mmHg, pulmonary artery wedge pressure ≤15 mmHg, and pulmonary vascular resistance ≥3 Wood units. All findings were documented in a structured proforma and analysed in SPSS. Results: The mean age of participants was 55.40 ± 9.76 years. Among them, 71 (54.6%) were male and 59 (45.4%) were female. In this study, porto-pulmonary hypertension was observed in 14 patients (10.77%) with hepatic cirrhosis. Among males, 4 (5.6%) had portopulmonary hypertension, compared to 10 (16.9%) females (p = 0.038*). Conclusion: Based on the findings of this study, it can be concluded that portopulmonary hypertension was present in 10.77% of patients with hepatic cirrhosis, with a higher prevalence observed among females.
Downloads
References
1. Enenche, A. A., Kweki, A., Aiwuyo, H. O., Akinti, O., Nevolina, A., Perry, J. C., Ayinalem, Y., Osarenkhoe, J. O., Ukenenye, E., Poluyi, C. O., & Ibrahim, A. O. (2024). Prevalence of pulmonary hypertension in liver cirrhosis patients: A cross-sectional analytical study. Cureus.
https://doi.org/10.7759/cureus.57313
2. Savale, L., Guimas, M., Ebstein, N., Fertin, M., Jevnikar, M., Renard, S., Horeau-Langlard, D., Tromeur, C., Chabanne, C., Prevot, G., Chaouat, A., Moceri, P., Artaud-Macari, É., Degano, B., Tresorier, R., Boissin, C., Bouvaist, H., Simon, A., Riou, M., … Sitbon, O. (2020). Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 73(1), 130-139.
https://doi.org/10.1016/j.jhep.2020.02.021
3. Atsukawa, M., Tsubota, A., Hatano, M., Kondo, C., Shioda, K., Ohno, H., Kawano, T., Hayama, K., Arai, T., Nakagawa‐Iwashita, A., Itokawa, N., Kaneko, K., Yoshida, Y., Koeda, M., Okubo, T., Yamamoto, T., Yamamoto, T., Taniai, N., Yoshida, H., … Iwakiri, K. (2020). Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization. Hepatology Research, 50(11), 1244-1254.
https://doi.org/10.1111/hepr.13560
4. Navarro-Vergara, D. I., Roldan-Valadez, E., Cueto-Robledo, G., & Jurado-Hernandez, M. Y. (2021). Portopulmonary hypertension: Prevalence, clinical and hemodynamic features. Current Problems in Cardiology, 46(3), 100747.
https://doi.org/10.1016/j.cpcardiol.2020.100747
5. Lai, Y. K., & Kwo, P. Y. (2023). Portopulmonary hypertension. Clinics in Liver Disease, 27(1), 71-84.
https://doi.org/10.1016/j.cld.2022.08.002
6. Jasso-Baltazar, E. A., Peña-Arellano, G. A., Aguirre-Valadez, J., Ruiz, I., Papacristofilou-Riebeling, B., Jimenez, J. V., García-Carrera, C. J., Rivera-López, F. E., Rodriguez-Andoney, J., Lima-Lopez, F. C., Hernández-Oropeza, J. L., Díaz, J. A., Kauffman-Ortega, E., Ruiz-Manriquez, J., Hernández-Reyes, P., Zamudio-Bautista, J., Rodriguez-Osorio, C. A., Pulido, T., Muñoz-Martínez, S., … García-Juárez, I. (2023). Portopulmonary hypertension: An updated review. Transplantation Direct, 9(8), e1517.
https://doi.org/10.1097/txd.0000000000001517
7. Frost, A., Badesch, D., Gibbs, J. S., Gopalan, D., Khanna, D., Manes, A., Oudiz, R., Satoh, T., Torres, F., & Torbicki, A. (2018). Diagnosis of pulmonary hypertension. European Respiratory Journal, 53(1), 1801904.
https://doi.org/10.1183/13993003.01904-2018
8. Weatherald, J., Boucly, A., Chemla, D., Savale, L., Peng, M., Jevnikar, M., Jaïs, X., Taniguchi, Y., O’Connell, C., Parent, F., Sattler, C., Hervé, P., Simonneau, G., Montani, D., Humbert, M., Adir, Y., & Sitbon, O. (2018). Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation, 137(7), 693-704.
https://doi.org/10.1161/circulationaha.117.029254
9. Shao, Y., Yin, X., Qin, T., Zhang, R., Zhang, Y., & Wen, X. (2021). Prevalence and associated factors of Portopulmonary hypertension in patients with Portal hypertension: A case‐control study. BioMed Research International, 2021(1).
https://doi.org/10.1155/2021/5595614
10. Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019). Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 53(1), 1801913.
https://doi.org/10.1183/13993003.01913-2018
11. Ruopp, N. F., & Cockrill, B. A. (2022). Diagnosis and treatment of pulmonary arterial hypertension. JAMA, 327(14), 1379.
https://doi.org/10.1001/jama.2022.4402
12. Delcroix, M., Torbicki, A., Gopalan, D., Sitbon, O., Klok, F. A., Lang, I., Jenkins, D., Kim, N. H., Humbert, M., Jais, X., Vonk Noordegraaf, A., Pepke-Zaba, J., Brénot, P., Dorfmuller, P., Fadel, E., Ghofrani, H., Hoeper, M. M., Jansa, P., Madani, M., … Simonneau, G. (2020). ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 57(6), 2002828.
https://doi.org/10.1183/13993003.02828-2020
13. Gupta, A., Pradhan, A., Mehrotra, S., Misra, R., Usman, K., Kumar, A., & Pandey, S. (2022). Prevalence and clinical features of Portopulmonary hypertension in patients with hepatic cirrhosis: An Echocardiographic study. Cureus.
https://doi.org/10.7759/cureus.24957
14. Poordad, F. F. (2015). Presentation and complications associated with cirrhosis of the liver. Current Medical Research and Opinion, 31(5), 925-937.
https://doi.org/10.1185/03007995.2015.1021905
15. Shah, N., Pourkazemi, Y., Hojnowski, K., & Cornella, S. (2015). Management options in decompensated cirrhosis. Hepatic Medicine: Evidence and Research, 43.
https://doi.org/10.2147/hmer.s62463
16. Ahmad G, Butt NI, Ashfaq F, Khan AA, Nazir M, Raheem R. Prevalence of pulmonary hypertension in patients of chronic liver disease. Rawal Medical Journal. 2021;46(4):792-4
17. Bozbas, S., & Eyuboglu, F. (2011). Evaluation of liver transplant candidates: A pulmonary perspective. Annals of Thoracic Medicine, 6(3), 109.
https://doi.org/10.4103/1817-1737.82436
18. Gurghean, A. V., & Tudor, I. A. (2017). Pulmonary hypertension in patients with hepatic cirrhosis and Portal hypertension. An echographic study. Medicine and Pharmacy Reports, 90(2), 161-165.
https://doi.org/10.15386/cjmed-705
19. Chiva, T., Ripoll, C., Sarnago, F., Rincón, D., Gómez‐Camarero, J., Galindo, E., Catalina, M., Elizaga, J., & Bañares, R. (2014). Characteristic haemodynamic changes of cirrhosis may influence the diagnosis of portopulmonary hypertension. Liver International, 35(2), 353-361.
https://doi.org/10.1111/liv.12562
20. CHEN, H., XING, S., XU, W., YANG, F., QI, X., WANG, L., & YANG, C. (2013). Portopulmonary hypertension in cirrhotic patients: Prevalence, clinical features and risk factors. Experimental and Therapeutic Medicine, 5(3), 819-824.
https://doi.org/10.3892/etm.2013.918
21. Kawut, S. M., Krowka, M. J., Trotter, J. F., Roberts, K. E., Benza, R. L., Badesch, D. B., Taichman, D. B., Horn, E. M., Zacks, S., Kaplowitz, N., Brown, R. S., & Fallon, M. B. (2008). Clinical risk factors for portopulmonary hypertension†. Hepatology, 48(1), 196-203.
https://doi.org/10.1002/hep.22275
22. Al‐Naamani, N., Krowka, M. J., Forde, K. A., Krok, K. L., Feng, R., Heresi, G. A., Dweik, R. A., Bartolome, S., Bull, T. M., Roberts, K. E., Austin, E. D., Hemnes, A. R., Patel, M. J., Oh, J. K., Lin, G., Doyle, M. F., Denver, N., Andrew, R., & MacLean, M. R. (2020). Estrogen signaling and Portopulmonary hypertension: The pulmonary vascular complications of liver disease study (PVCLD2). Hepatology, 73(2), 726-737.
https://doi.org/10.1002/hep.31314
23. Nadeem, M. A., Waseem, T., Sheikh, A. M., Grumman, N., Irfan, K., & Hasnain, S. S. (2002). Hepatitis C virus: an alarmingly increasing cause of liver cirrhosis in Pakistan. Pak J Gastroenterol, 16(1), 3-8.
24. Farooqi, R. J., Farooqi, J. I., ur Rehman, M., Ahmad, H., Ahmad, F., & Gul, S. (2005). Outcome after injection sclerotherapy for esophageal variceal bleeding in patients with liver cirrhosis and COPD. Journal of Postgraduate Medical Institute, 19(1).
25. Intekhab, A., Iqbal, H., M Amjad, T., & Muhammad, N. (2005). Spectrum of precipitating factors of hepatic encephalopathy in liver cirrhosis. Pak J Med Res. 2005;44(2):96-100.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
